

# T Yau

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5800453/publications.pdf>

Version: 2024-02-01

82  
papers

9,461  
citations

94269

37  
h-index

60497

81  
g-index

85  
all docs

85  
docs citations

85  
times ranked

10421  
citing authors

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 1  | Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. <i>Lancet, The</i> , 2017, 389, 2492-2502.  | 6.3 | 3,224     |
| 2  | Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 193-202.  | 0.8 | 1,255     |
| 3  | Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib. <i>JAMA Oncology</i> , 2020, 6, e204564.  | 3.4 | 746       |
| 4  | Development of Hong Kong Liver Cancer Staging System With Treatment Stratification for Patients With Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2014, 146, 1691-1700.e3.  | 0.6 | 576       |
| 5  | CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC). <i>Annals of Oncology</i> , 2019, 30, v874-v875.                              | 0.6 | 512       |
| 6  | Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis. <i>Journal of Hepatology</i> , 2019, 71, 543-552.   | 1.8 | 180       |
| 7  | Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population. <i>Cancer</i> , 2009, 115, 428-436.  | 2.0 | 136       |
| 8  | Incidence, pattern and timing of brain metastases among patients with advanced breast cancer treated with trastuzumab. <i>Acta Oncologica</i> , 2006, 45, 196-201.   | 0.8 | 131       |
| 9  | Genomic Profiling of Intrahepatic Cholangiocarcinoma: Refining Prognosis and Identifying Therapeutic Targets. <i>Annals of Surgical Oncology</i> , 2014, 21, 3827-3834.  | 0.7 | 123       |
| 10 | Circulating Oncometabolite 2-Hydroxyglutarate Is a Potential Surrogate Biomarker in Patients with Isocitrate Dehydrogenase-Mutant Intrahepatic Cholangiocarcinoma. <i>Clinical Cancer Research</i> , 2014, 20, 1884-1890.  | 3.2 | 110       |
| 11 | Treatment Outcomes in Anaplastic Thyroid Carcinoma: Survival Improvement in Young Patients With Localized Disease Treated by Combination of Surgery and Radiotherapy. <i>Annals of Surgical Oncology</i> , 2008, 15, 2500-2505.  | 0.7 | 99        |
| 12 | The Significance of Early Alpha-Fetoprotein Level Changes in Predicting Clinical and Survival Benefits in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib. <i>Oncologist</i> , 2011, 16, 1270-1279.   | 1.9 | 98        |
| 13 | Nivolumab (NIVO) + ipilimumab (IPI) + cabozantinib (CABO) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040.. <i>Journal of Clinical Oncology</i> , 2020, 38, 478-478.   | 0.8 | 93        |
| 14 | <sup>11</sup> C-Acetate and <sup>18</sup> F-FDG PET/CT for Clinical Staging and Selection of Patients with Hepatocellular Carcinoma for Liver Transplantation on the Basis of Milan Criteria: Surgeon's Perspective. <i>Journal of Nuclear Medicine</i> , 2013, 54, 192-200. | 2.8 | 89        |
| 15 | A phase 1 dose-escalating study of pegylated recombinant human arginase 1 (Peg-rhArg1) in patients with advanced hepatocellular carcinoma. <i>Investigational New Drugs</i> , 2013, 31, 99-107.  | 1.2 | 88        |
| 16 | Randomized phase II study of axitinib versus placebo plus best supportive care in second-line treatment of advanced hepatocellular carcinoma. <i>Annals of Oncology</i> , 2015, 26, 2457-2463.   | 0.6 | 85        |
| 17 | Phase I Dose-Finding Study of Pazopanib in Hepatocellular Carcinoma: Evaluation of Early Efficacy, Pharmacokinetics, and Pharmacodynamics. <i>Clinical Cancer Research</i> , 2011, 17, 6914-6923.  | 3.2 | 81        |
| 18 | Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors. , 2021, 9, e001945.  |     | 74        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 19 | Management of colon cancer: resource-stratified guidelines from the Asian Oncology Summit 2012. <i>Lancet Oncology</i> , The, 2012, 13, e470-e481.   | 5.1 | 70        |
| 20 | Preliminary efficacy, safety, pharmacokinetics, pharmacodynamics and quality of life study of pegylated recombinant human arginase 1 in patients with advanced hepatocellular carcinoma. <i>Investigational New Drugs</i> , 2015, 33, 496-504. | 1.2 | 67        |
| 21 | Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2013, 59, 1271-1277.   | 1.8 | 66        |
| 22 | Management of advanced hepatocellular carcinoma in the era of targeted therapy. <i>Liver International</i> , 2009, 29, 10-17.  | 1.9 | 65        |
| 23 | The use of single-agent sorafenib in the treatment of advanced hepatocellular carcinoma patients with underlying Child-Pugh B liver cirrhosis. <i>Cancer</i> , 2012, 118, 5293-5301.   | 2.0 | 65        |
| 24 | The Outcomes and Safety of Single-Agent Sorafenib in the Treatment of Elderly Patients with Advanced Hepatocellular Carcinoma (HCC). <i>Oncologist</i> , 2011, 16, 1721-1728.  | 1.9 | 63        |
| 25 | Phase II study of bevacizumab and erlotinib in the treatment of advanced hepatocellular carcinoma patients with sorafenib-refractory disease. <i>Investigational New Drugs</i> , 2012, 30, 2384-2390.  | 1.2 | 61        |
| 26 | A new prognostic score system in patients with advanced hepatocellular carcinoma not amendable to locoregional therapy. <i>Cancer</i> , 2008, 113, 2742-2751.  | 2.0 | 58        |
| 27 | Presence of an in situ component is associated with reduced biological aggressiveness of size-matched invasive breast cancer. <i>British Journal of Cancer</i> , 2010, 102, 1391-1396.   | 2.9 | 56        |
| 28 | Outcome of laparoscopic versus open hepatectomy for colorectal liver metastases. <i>ANZ Journal of Surgery</i> , 2013, 83, 847-852.  | 0.3 | 56        |
| 29 | Targeted Therapy in the Management of Advanced Gastric Cancer: Are We Making Progress in the Era of Personalized Medicine?. <i>Oncologist</i> , 2012, 17, 346-358.   | 1.9 | 55        |
| 30 | Evolution of systemic therapy of advanced hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2008, 14, 6437.   | 1.4 | 55        |
| 31 | Longitudinal Assessment of Quality of Life in Rectal Cancer Patients With or Without Stomas Following Primary Resection. <i>Diseases of the Colon and Rectum</i> , 2009, 52, 669-677.  | 0.7 | 54        |
| 32 | The ophthalmological complications of targeted agents in cancer therapy: what do we need to know as ophthalmologists?. <i>Acta Ophthalmologica</i> , 2013, 91, 604-609.  | 0.6 | 53        |
| 33 | Integrating Molecular Mechanisms and Clinical Evidence in the Management of Trastuzumab Resistant or Refractory HER-2+ Metastatic Breast Cancer. <i>Oncologist</i> , 2011, 16, 1535-1546.  | 1.9 | 50        |
| 34 | Cabozantinib in combination with atezolizumab versus sorafenib in treatment-naive advanced hepatocellular carcinoma: COSMIC-312 Phase III study design. <i>Future Oncology</i> , 2020, 16, 1525-1536.  | 1.1 | 50        |
| 35 | Complications of traditional Chinese/herbal medicines (TCM) – a guide for perplexed oncologists and other cancer caregivers. <i>Supportive Care in Cancer</i> , 2009, 17, 231-240.   | 1.0 | 44        |
| 36 | The outcomes of elderly patients with hepatocellular carcinoma treated with transarterial chemoembolization. <i>Cancer</i> , 2009, 115, 5507-5515.   | 2.0 | 43        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 37 | Molecular targeted therapies in advanced gastric cancer: does tumor histology matter?. Therapeutic Advances in Gastroenterology, 2013, 6, 15-31.   | 1.4 | 43        |
| 38 | Hong Kong Consensus Recommendations on the Management of Hepatocellular Carcinoma. Liver Cancer, 2015, 4, 51-69.   | 4.2 | 43        |
| 39 | Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib. European Journal of Cancer, 2022, 167, 1-12.   | 1.3 | 43        |
| 40 | Is There a Role for Unstimulated Thyroglobulin Velocity in Predicting Recurrence in Papillary Thyroid Carcinoma Patients with Detectable Thyroglobulin after Radioiodine Ablation?. Annals of Surgical Oncology, 2012, 19, 3479-3485.                            | 0.7 | 38        |
| 41 | Surveillance in Stage I Seminoma Patients: A Long-Term Assessment. European Urology, 2010, 57, 673-678.  | 0.9 | 37        |
| 42 | Nivolumab (NIVO) plus ipilimumab (IPI) combination therapy in patients (Pts) with advanced hepatocellular carcinoma (aHCC): Long-term results from CheckMate 040.. Journal of Clinical Oncology, 2021, 39, 269-269.  | 0.8 | 37        |
| 43 | Placental growth factor promotes tumour desmoplasia and treatment resistance in intrahepatic cholangiocarcinoma. Gut, 2022, 71, 185-193.   | 6.1 | 34        |
| 44 | Clonal Evolutionary Analysis during HER2 Blockade in HER2-Positive Inflammatory Breast Cancer: A Phase II Open-Label Clinical Trial of Afatinib +/- Vinorelbine. PLoS Medicine, 2016, 13, e1002136.  | 3.9 | 28        |
| 45 | Efficacy and Tolerability of Low-Dose Thalidomide as First-Line Systemic Treatment of Patients with Advanced Hepatocellular Carcinoma. Oncology, 2007, 72, 67-71.  | 0.9 | 27        |
| 46 | Phase 1 trial of PTK787/ZK222584 combined with intravenous doxorubicin for treatment of patients with advanced hepatocellular carcinoma. Cancer, 2010, 116, 5022-5029.   | 2.0 | 23        |
| 47 | The Clinicopathological Significance of miR-133a in Colorectal Cancer. Disease Markers, 2014, 2014, 1-8.   | 0.6 | 22        |
| 48 | Bevacizumab-based therapy for advanced small bowel adenocarcinoma. Gut, 2008, 57, 1631-1632.   | 6.1 | 20        |
| 49 | Transcatheter arterial chemoembolization is safe and effective for elderly advanced hepatocellular carcinoma patients: results from an international database. Liver International, 2014, 34, 1109-1117.   | 1.9 | 19        |
| 50 | Efficacy, Tolerability, and Biomarker Analyses of Once-Every-2-Weeks Cetuximab Plus First-Line FOLFOX or FOLFIRI in Patients With KRAS or All RAS Wild-Type Metastatic Colorectal Cancer: The Phase 2 APEC Study. Clinical Colorectal Cancer, 2017, 16, e73-e88. | 1.0 | 19        |
| 51 | Coexisting ductal carcinoma in situ independently predicts lower tumor aggressiveness in node-positive luminal breast cancer. Medical Oncology, 2012, 29, 1536-1542.   | 1.2 | 17        |
| 52 | Androgen Deprivation Therapy and Cardiovascular Risk in Chinese Patients with Nonmetastatic Carcinoma of Prostate. Journal of Oncology, 2014, 2014, 1-6.   | 0.6 | 17        |
| 53 | Preemptive adefovir versus lamivudine for prevention of hepatitis B reactivation in chronic hepatitis B patients undergoing chemotherapy. Hepatology International, 2015, 9, 224-230.  | 1.9 | 17        |
| 54 | Nivolumab + Ipilimumab for patients with hepatocellular carcinoma previously treated with Sorafenib. Expert Review of Gastroenterology and Hepatology, 2021, 15, 589-598.  | 1.4 | 17        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 55 | Efficacy and Tolerability of Adjuvant Oral Capecitabine plus Intravenous Oxaliplatin (XELOX) in Asian Patients with Colorectal Cancer: 4-Year Analysis. <i>Asian Pacific Journal of Cancer Prevention</i> , 2013, 14, 6585-6590.                            | 0.5 | 16        |
| 56 | Novel systemic therapy for hepatocellular carcinoma. <i>Hepatology International</i> , 2020, 14, 638-651.   | 1.9 | 15        |
| 57 | PPI-Delayed Diagnosis of Gastrinoma: Oncologic Victim of Pharmacologic Success. <i>Pathology and Oncology Research</i> , 2010, 16, 87-91.   | 0.9 | 13        |
| 58 | Lobular breast cancers lack the inverse relationship between ER/PR status and cell growth rate characteristic of ductal cancers in two independent patient cohorts: implications for tumor biology and adjuvant therapy. <i>BMC Cancer</i> , 2014, 14, 826. | 1.1 | 13        |
| 59 | The real-world use of regorafenib for metastatic colorectal cancer: multicentre analysis of treatment pattern and outcomes in Hong Kong. <i>Postgraduate Medical Journal</i> , 2017, 93, 395-400.   | 0.9 | 13        |
| 60 | Review article: current management of metastatic colorectal cancer – the evolving impact of targeted drug therapies. <i>Alimentary Pharmacology and Therapeutics</i> , 2008, 27, 997-1005.  | 1.9 | 12        |
| 61 | Molecular targeted therapy of advanced hepatocellular carcinoma beyond sorafenib. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 2187-2198.   | 0.9 | 12        |
| 62 | Common Malignancies With Uncommon Sites of Presentation. <i>Journal of Clinical Oncology</i> , 2003, 21, 4456-4458.   | 0.8 | 11        |
| 63 | A phase 1 study of pegylated recombinant arginase (PEG-BCT-100) in combination with systemic chemotherapy (capecitabine and oxaliplatin) [PACOX] in advanced hepatocellular carcinoma patients. <i>Investigational New Drugs</i> , 2022, 40, 314-321.       | 1.2 | 11        |
| 64 | A case of mixed adult Wilms' tumour and angiosarcoma responsive to carboplatin, etoposide and vincristine (CEO). <i>Cancer Chemotherapy and Pharmacology</i> , 2008, 61, 717-720.   | 1.1 | 10        |
| 65 | High-intensity focused ultrasound as a treatment for colorectal liver metastasis in difficult position. <i>International Journal of Colorectal Disease</i> , 2012, 27, 987-988.   | 1.0 | 10        |
| 66 | Intramuscular recurrence in a Hepatocellular carcinoma patient with indolent disease course. <i>World Journal of Surgical Oncology</i> , 2008, 6, 42.   | 0.8 | 9         |
| 67 | Advanced Pancreatic Cancer: Flourishing Novel Approaches in the Era of Biological Therapy. <i>Oncologist</i> , 2014, 19, 937-950.   | 1.9 | 9         |
| 68 | Thyroid Immune-Related Adverse Events in Patients with Cancer Treated with anti-PD1/anti-CTLA4 Immune Checkpoint Inhibitor Combination: Clinical Course and Outcomes. <i>Endocrine Practice</i> , 2021, 27, 886-893.  | 1.1 | 9         |
| 69 | The Use of Cabozantinib in Advanced Hepatocellular Carcinoma in Hong Kong – A Territory-Wide Cohort Study. <i>Cancers</i> , 2021, 13, 2002.   | 1.7 | 8         |
| 70 | Metastatic Pancreatic Cancer: Are We Making Progress in Treatment?. <i>Gastroenterology Research and Practice</i> , 2012, 2012, 1-6.  | 0.7 | 7         |
| 71 | Long Term Survival Analysis of Hepatectomy for Neuroendocrine Tumour Liver Metastases. <i>Scientific World Journal</i> , The, 2014, 2014, 1-7.  | 0.8 | 7         |
| 72 | The Outcomes of Systemic Treatment in Recurrent Hepatocellular Carcinomas Following Liver Transplants. <i>Advances in Therapy</i> , 2021, 38, 3900-3910.  | 1.3 | 7         |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 73 | In-Silico Analysis of Monoclonal Antibodies against SARS-CoV-2 Omicron. <i>Viruses</i> , 2022, 14, 390.  | 1.5 | 7         |
| 74 | An overview in management of hepatocellular carcinoma in Hong Kong using the Hong Kong Liver Cancer (HKLC) staging system. <i>Global Health &amp; Medicine</i> , 2020, 2, 312-318.                             | 0.6 | 6         |
| 75 | Advances in the Systemic Treatment of Neuroendocrine Tumors in the Era of Molecular Therapy. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2013, 13, 382-388.   | 0.9 | 5         |
| 76 | Breast and pelvic masses in a myeloma patient. <i>Annals of Hematology</i> , 2008, 87, 1027-1029.  | 0.8 | 4         |
| 77 | Hoarseness during treatment with bevacizumab and other vascular endothelial growth factor signalling inhibitors. <i>Acta OncolÃ³gica</i> , 2009, 48, 1213-1215.  | 0.8 | 4         |
| 78 | Transient Carcinoembryonic Antigen Elevations During Adjuvant Chemotherapy for Colorectal Cancer Reflect the Burden of Residual Micrometastatic Disease. <i>Clinical Colorectal Cancer</i> , 2010, 9, 108-112. | 1.0 | 3         |
| 79 | Massive rectal bleeding in a patient with a history of hepatocellular carcinoma. <i>Gut</i> , 2008, 57, 1412-1412.   | 6.1 | 2         |
| 80 | Editorial to "Palbociclib and letrozole in advanced breast cancer". <i>Translational Cancer Research</i> , 2017, 6, S376-S379.   | 0.4 | 2         |
| 81 | Does hepatitis B seroconversion affect survival outcome in patients with hepatitis B related hepatocellular carcinoma?. <i>Translational Gastroenterology and Hepatology</i> , 2016, 1, 51-51.                 | 1.5 | 1         |
| 82 | What determines treatment success and future perspectives?. <i>Postgraduate Medical Journal</i> , 2016, 92, 123-124.   | 0.9 | 0         |